Please assess the completion status of the following clinical trial:

Trial Title: TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has 3 or more primary protease inhibitor mutations~* documented genotypic evidence of resistance to currently available NNRTIs by having at least 1 NNRTI (non-nucleoside reverse transcriptase inhibitors) resistance-associated mutation~* on a stable antiretroviral therapy for at least 8 weeks~* plasma viral load at screening visit \> 5000 HIV-1 RNA copies/mL.~Exclusion Criteria:~* Active AIDS defining illnesses (except for stable, cutaneous Kaposi's Sarcoma or wasting syndrome)~* Any grade 3 or grade 4 toxicity according to the DAIDS grading scale~* Use of disallowed concurrent therapy~* Any active clinically significant disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 002 (Type: PLACEBO_COMPARATOR): Placebo 2 tablets b.i.d.96 weeks
- 001 (Type: ACTIVE_COMPARATOR): TMC125 2 X100 mg tablets b.i.d.96 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).